RU2718056C2 - Способы лечения фиброзного рака - Google Patents

Способы лечения фиброзного рака Download PDF

Info

Publication number
RU2718056C2
RU2718056C2 RU2016117775A RU2016117775A RU2718056C2 RU 2718056 C2 RU2718056 C2 RU 2718056C2 RU 2016117775 A RU2016117775 A RU 2016117775A RU 2016117775 A RU2016117775 A RU 2016117775A RU 2718056 C2 RU2718056 C2 RU 2718056C2
Authority
RU
Russia
Prior art keywords
sap
treatment
patient
agonist
cancer
Prior art date
Application number
RU2016117775A
Other languages
English (en)
Russian (ru)
Other versions
RU2016117775A (ru
RU2016117775A3 (https=
Inventor
Сьюзан БРУН
Элизабет ТРЕХУ
Марк ЛЮФЕР
Original Assignee
Промедиор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Промедиор, Инк. filed Critical Промедиор, Инк.
Publication of RU2016117775A publication Critical patent/RU2016117775A/ru
Publication of RU2016117775A3 publication Critical patent/RU2016117775A3/ru
Application granted granted Critical
Publication of RU2718056C2 publication Critical patent/RU2718056C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2016117775A 2013-10-08 2014-10-08 Способы лечения фиброзного рака RU2718056C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361888269P 2013-10-08 2013-10-08
US61/888,269 2013-10-08
US201461992807P 2014-05-13 2014-05-13
US61/992,807 2014-05-13
US201462004836P 2014-05-29 2014-05-29
US201462004828P 2014-05-29 2014-05-29
US62/004,828 2014-05-29
US62/004,836 2014-05-29
PCT/US2014/059699 WO2015054390A1 (en) 2013-10-08 2014-10-08 Methods for treating fibrotic cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020111934A Division RU2020111934A (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака

Publications (3)

Publication Number Publication Date
RU2016117775A RU2016117775A (ru) 2017-11-15
RU2016117775A3 RU2016117775A3 (https=) 2018-07-27
RU2718056C2 true RU2718056C2 (ru) 2020-03-30

Family

ID=52813618

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016117775A RU2718056C2 (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака
RU2020111934A RU2020111934A (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020111934A RU2020111934A (ru) 2013-10-08 2014-10-08 Способы лечения фиброзного рака

Country Status (10)

Country Link
US (2) US11020451B2 (https=)
EP (2) EP3718558A1 (https=)
JP (2) JP6636914B2 (https=)
CN (2) CN105792831A (https=)
AU (2) AU2014331954B2 (https=)
CA (1) CA2926418A1 (https=)
ES (1) ES2784234T3 (https=)
PL (1) PL3054959T3 (https=)
RU (2) RU2718056C2 (https=)
WO (1) WO2015054390A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2851445C1 (ru) * 2020-08-03 2025-11-24 Индерес Лтд Комбинация лекарственных средств и ее применение в лечении рака

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105792831A (zh) 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法
CA2983004A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
US10960006B2 (en) * 2018-01-31 2021-03-30 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
KR20200139721A (ko) * 2018-03-28 2020-12-14 블레이드 테라퓨틱스, 인크. 섬유성 질환을 치료하는 방법
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
WO2020219423A1 (en) * 2019-04-25 2020-10-29 Clear Creek Bio, Inc. Combination therapies including inhibitors of dihydroorotate dehydrogenase
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
JP7850665B2 (ja) * 2020-01-28 2026-04-23 ラジエル セラピューティクス エルティーディー． 血管脂肪腫の処置のための組成物
KR102725907B1 (ko) * 2021-11-25 2024-11-04 성균관대학교산학협력단 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법
KR20260016906A (ko) * 2023-03-17 2026-02-04 엠디엑스 메니지먼트 엘엘씨 요법의 유해효과를 개선하기 위한 조성물 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080044429A1 (en) * 2006-06-26 2008-02-21 Macrogenics, Inc. Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof
US20090202520A1 (en) * 2007-07-06 2009-08-13 Promedior, Inc. Treatment and diagnostic methods for fibrosis related disorders
RU2419450C2 (ru) * 2005-04-14 2011-05-27 Вайет Способы лечения и профилактики фиброза антагонистами il-21/il-21r

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
CN101166539B (zh) * 2005-02-08 2012-01-04 得克萨斯大学体系董事会 用于治疗癌症的涉及mda-7的组合物和方法
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
WO2009009034A2 (en) * 2007-07-06 2009-01-15 Promedior, Inc Methods and compositions useful in the treatment of mucositis
CA2755047C (en) 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
US20100266643A1 (en) 2009-04-01 2010-10-21 Willett W Scott Pulmonary and nasal delivery of serum amyloid p
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
US20130195861A1 (en) 2011-12-21 2013-08-01 Promedior, Inc. Serum amyloid p-antibody fusion proteins
JP2015069119A (ja) 2013-09-30 2015-04-13 パナソニック液晶ディスプレイ株式会社 表示装置
CN105792831A (zh) 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法
CA2983004A1 (en) 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2419450C2 (ru) * 2005-04-14 2011-05-27 Вайет Способы лечения и профилактики фиброза антагонистами il-21/il-21r
US20080044429A1 (en) * 2006-06-26 2008-02-21 Macrogenics, Inc. Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof
US20090202520A1 (en) * 2007-07-06 2009-08-13 Promedior, Inc. Treatment and diagnostic methods for fibrosis related disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUFFIELD JS et al. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis//Drug News Perspect. 2010 Jun;23(5):305-15. doi: 10.1358/dnp.2010.23.5.1444206.PMID: 20603654 DOI: 10.1358/dnp.2010.23.5.1444206. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2851445C1 (ru) * 2020-08-03 2025-11-24 Индерес Лтд Комбинация лекарственных средств и ее применение в лечении рака

Also Published As

Publication number Publication date
EP3718558A1 (en) 2020-10-07
CN105792831A (zh) 2016-07-20
EP3054959A4 (en) 2017-04-26
WO2015054390A1 (en) 2015-04-16
JP2016539087A (ja) 2016-12-15
RU2016117775A (ru) 2017-11-15
JP2020059752A (ja) 2020-04-16
JP6636914B2 (ja) 2020-01-29
US11020451B2 (en) 2021-06-01
PL3054959T3 (pl) 2020-07-13
RU2020111934A (ru) 2020-04-29
CN114053395A (zh) 2022-02-18
AU2020220139A1 (en) 2020-09-10
EP3054959B1 (en) 2020-01-08
ES2784234T3 (es) 2020-09-23
EP3054959A1 (en) 2016-08-17
US20160235812A1 (en) 2016-08-18
JP7140739B2 (ja) 2022-09-21
US20210322515A1 (en) 2021-10-21
CA2926418A1 (en) 2015-04-16
RU2016117775A3 (https=) 2018-07-27
AU2014331954B2 (en) 2020-05-21
AU2014331954A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
RU2718056C2 (ru) Способы лечения фиброзного рака
US20230041964A1 (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof
ES2385924T3 (es) Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
US10039838B2 (en) Car peptide for homing, diagnosis and targeted therapy for pulmonary and fibrotic disorders
JP2018512164A (ja) 骨髄増殖性障害を処置するための方法
ES2563748T3 (es) Derivados de amiloide P sérico y su preparación y uso
HK40039408A (en) Methods for treating fibrotic cancers
HK40069679A (en) Methods for treating fibrotic cancers
WO2014093870A2 (en) Use of c-c chemokine receptor type 7 (ccr7) inhibitors
HK1226660B (en) Methods for treating fibrotic cancers
HK1226660A1 (en) Methods for treating fibrotic cancers
KR20220149781A (ko) NF-κB 억제제의 엑소솜 기반 전달의 사용
US20040009920A1 (en) Methods and compositions for inhibiting tumor growth and angiogenesis